Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
Tvardi to go public via merger with cash-strapped Cara
Pruritus drug developer Cara kicked off the year halving its headcount and has now found a new home via a merger with fibrosis disease-focused Tvardi.
James Waldron
Dec 18, 2024 10:37am
PureTech's lung fibrosis drug slows decline in phase 2 trial
Dec 16, 2024 7:00am
After phase 2 data, Insilico plots pivotal lung disease trial
Nov 12, 2024 1:34pm
The Column Group biotech taps Surrozen to target lung fibrosis
Nov 4, 2024 11:14am
Amgen disappears lung disease program after phase 2 fail
Oct 30, 2024 5:59pm
Novartis channels Gargamel, terminating midphase SMURF1 trial
Oct 14, 2024 9:14am
